HempTalk - Business Blogs and Press Releases
Project CBD Newsletter: CBD Bioavailability and Delivery Methods, Psychedelic Trial Safety Concerns, Endocannabinoid System Research, and Ibogaine’s Effects on Veterans
This week’s newsletter covers an Iranian study on CBD bioavailability and delivery methods, critiques of Canada’s cannabis market and flavored vape policy, therapist concerns around psychedelic trials, and new research on the endocannabinoid system’s connections to insulin, artificial sweeteners, ibogaine, endometriosis pain, and the gut-liver axis.
Noteworthy Read
CBD Bioavailability and Delivery Methods (Iranian Journal of Basic Medical Sciences)
In a recent study, Iranian scientists looked at how CBD works in the body and why it can be difficult to turn into reliable medicines. Because CBD does not dissolve well in water and is heavily processed by the liver, researchers explored different delivery methods — including capsules, mouth sprays, skin patches, inhaled products, and nano-formulations — to help increase bioavailability. The paper also reviews CBD’s potential applications across inflammation, pain, neurological conditions, cancer-related pathways, and metabolic disorders.
Download the PDF
View more in CBD
More Noteworthy Reading
The Canadian Cannabis Industry Is a Cesspit (WTF Canada)
This editorial argues that Canada’s legal cannabis market has fallen short of its early medical, cultural, and educational promise, with a pointed critique of the commercialization, regulation, and product culture that has developed since legalization took effect.
Report Details How Trump Did Big Tobacco’s Bidding on Flavored Vapes Despite Risk to Kids (CommonDreams)
Common Dreams reports on allegations that the Trump administration moved to loosen restrictions on flavored vape products following pressure from tobacco and vaping industry interests.
Read more
View more in Synthetic Cannabinoids
Therapists Express Concerns Over Safety and Ethics of Psychedelic Trials (Ecstatic Integration)
Jules Evans reports that psychedelic trial therapists have raised concerns about inadequate preparation, limited informed consent, weak adverse-event monitoring, SSRI washout risks, and the growing push to minimize the therapy component of psychedelic-assisted treatment.
Read more
View more in Psychedelics
Research Round-Up
Insulin Increases Cannabinoid CB1 Receptor Expression (PubMed)
A new study examines how insulin may increase expression of the cannabinoid CB1 receptor, adding another layer to the relationship between metabolic signaling and the endocannabinoid system. The findings may be relevant to research on insulin resistance, obesity, and cannabinoid-linked metabolic regulation.
Read more
View more in Endocannabinoid System
Artificial Sweeteners Disrupt Endocannabinoid Gene Expression (Frontiers of Behavioral Neuroscience)
New research suggests artificial sweeteners may alter endocannabinoid-related gene expression, raising questions about how non-nutritive sweeteners interact with metabolism, gut-brain signaling, and inflammatory pathways. The findings add to a growing body of work suggesting that “zero-calorie” sweeteners can have biologically active effects beyond taste.
Read more
View more in Endocannabinoid System
Brain Scans Reveal How Ibogaine Alters Neural Networks in Veterans With Head Trauma (PsyPost)
A neuroimaging study of male combat veterans with traumatic brain injury and PTSD found that ibogaine treatment was associated with changes in cerebral blood flow and broad reorganization of neural networks. The findings offer early mechanistic insight into ibogaine’s potential effects on injured brains, but the study was small, observational, and lacked a placebo control.
Read more
View more in Psychedelics
Medicinal Cannabis as Breakthrough for Endometriosis Pain (Streamline)
This report highlights growing clinical and patient interest in medicinal cannabis for endometriosis-related pelvic pain, a condition where conventional pain management and hormonal therapies are often inadequate or poorly tolerated.
CBD as Modulator of the Gut-Liver Axis: Implications for Hepatic and Metabolic Disorder Therapies (Bentham Science)
A new review examines CBD’s potential effects on the gut-liver axis, including gut barrier integrity, microbiota composition, inflammation, oxidative stress, lipid metabolism, and insulin sensitivity.
A heartfelt thank you to all of the CBD brands whose generous support makes it possible for Project CBD to bring you the latest plant medicine research and journalism each week — we couldn’t do this work without you.
The post Project CBD Newsletter: CBD Bioavailability and Delivery Methods, Psychedelic Trial Safety Concerns, Endocannabinoid System Research, and Ibogaine’s Effects on Veterans appeared first on Project CBD.
